Revolution Medicines, Inc. Stock Price, News & Analysis

Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company, has announced a public offering of common stock worth up to $600.0 million. The company plans to grant underwriters a 30-day option to purchase an additional $90.0 million of shares. J.P. Morgan, TD Cowen, Goldman Sachs & Co. and Guggenheim Securities will serve as joint book-running managers, with UBS Investment Bank as lead manager. The offering's completion depends on market conditions, with no guaranteed timeline or final terms.

Revolution Medicines announced clinical updates from its RAS(ON) inhibitor portfolio, highlighting progress in treating RAS-addicted cancers. The company reported compelling Phase 1/1b data for RMC-6236 in pancreatic cancer and non-small cell lung cancer. In pancreatic cancer patients, RMC-6236 showed a 36% objective response rate for KRAS G12X mutations. The drug demonstrated favorable safety profiles both as monotherapy and in combinations with pembrolizumab. Initial antitumor activity was observed in colorectal cancer patients using RMC-6236 and RMC-6291 combination therapy. The company plans to initiate Phase 3 trials, including RASolve 301 in Q1 2025.

Revolution Medicines (Nasdaq: RVMD) has announced a forthcoming investor webcast to provide clinical updates on their RAS(ON) inhibitor portfolio. The event, focused on their targeted therapies for RAS-addicted cancers, is scheduled for December 2, 2024, at 8:00 a.m. Eastern Time. The webcast will be accessible online, with a replay available on the company's website's Events & Presentations page for at least 14 days after the live event.

Revolution Medicines (RVMD) reported Q3 2024 financial results and clinical progress. The company announced a net loss of $156.3 million, up from $108.4 million in Q3 2023. R&D expenses increased to $151.8 million from $107.7 million year-over-year. The company maintains a strong cash position of $1.55 billion, expected to fund operations into 2027.

Key clinical highlights include the initiation of Phase 3 trial for RMC-6236 in pancreatic cancer patients and promising initial results for RMC-9805 in KRAS G12D mutation patients. The company reaffirmed its 2024 guidance projecting GAAP net loss between $560-600 million.

Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focused on RAS-addicted cancers, announces its participation in two major healthcare conferences. CEO Mark A. Goldsmith will present at Guggenheim's Inaugural Healthcare Innovation Conference on November 12, 2024, at 3:00 p.m. ET in Boston, and the UBS Global Healthcare Conference on November 13, 2024, at 5:00 p.m. ET in Rancho Palos Verdes. Both presentations will be available via webcast on the company's website, with replays accessible for at least 14 days after the events.

Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company, will report its financial results for the third quarter of 2024 on November 6, 2024, after market close.

A webcast hosted by senior management will follow at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the results and provide a corporate update. The webcast will be available live and as an archived replay on the company's website for at least 14 days.

Revolution Medicines announced preliminary safety and antitumor data for RMC-9805, its RAS(ON) G12D-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma (PDAC). The Phase 1/1b study included 179 patients treated with varying doses. At 1200 mg daily dose, the drug showed a 30% objective response rate and 80% disease control rate. The treatment demonstrated an encouraging safety profile with primarily Grade 1 adverse events, including GI-related toxicities and rash. No Grade 4 or 5 treatment-related adverse events were observed, and no patients discontinued treatment due to adverse events.

Revolution Medicines announced encouraging data for RMC-6236, its RAS(ON) multi-selective inhibitor, in treating pancreatic ductal adenocarcinoma (PDAC). The Phase 1/1b study included 127 patients treated with doses ranging from 160mg to 300mg daily. Key results showed median progression-free survival of 8.5 months and overall survival of 14.5 months in second-line KRAS G12X mutation patients. The treatment demonstrated a 29% objective response rate in second-line patients and showed manageable safety profile with primarily Grade 1 or 2 adverse events. The most common side effects were rash and GI-related toxicities, with no treatment discontinuations due to adverse events.

Revolution Medicines has announced the dosing of the first patient in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The global, randomized, open-label study will evaluate RMC-6236 monotherapy against standard chemotherapy in approximately 460 patients worldwide who have received one prior line of therapy.

The study focuses on patients with PDAC harboring specific RAS mutations. Primary endpoints are progression-free survival (PFS) and overall survival (OS) in the core patient population. This milestone marks a significant step in Revolution Medicines' mission to revolutionize treatment for RAS-addicted cancers, particularly PDAC, which has a five-year survival rate of only 3% in metastatic cases.